SequelSEC

Axogen, Inc. AXGN

Electromedical & Electrotherapeutic Apparatus · CIK 0000805928 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$266.93M
Fiscal year ended 2026-09-30
Operating income
-$13.80M
Fiscal year ended 2026-09-30
Free cash flow
$22.04M
Fiscal year ended 2026-09-30

Valuation, from the filing

Public float$430.70MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$8.30Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.9×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity3.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Electromedical & Electrotherapeutic Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio5.11x83th
Gross margin74.3%78th
Operating margin-3.5%71th
Net margin-7.0%67th
SBC / revenue13.4%67th
Revenue YoY growth20.2%61th
CapEx / revenue1.7%60th
FCF margin-1.3%60th
Long-term debt / equity0.38x50th
R&D / revenue14.6%50th

Axogen, Inc. (AXGN) reported revenue of $266.93M and net income of -$31.92M for the fiscal year ended 2026-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Axogen, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

Axogen, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Revenue$266.93M
Cost of revenue$68.92M
Gross profit$198.00M
Operating income-$13.80M
Net income-$31.92M
Research & development$37.43M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrative$174.38M
General & administrative$57.34M
Selling & marketing$117.03M

Balance

Axogen, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Cash & equivalents$328.89M
Total assets$550.34M
Current assets$438.09M
Total liabilities$54.24M
Current liabilities$36.46M
Total equity incl. NCI$496.10M
Temporary (mezzanine) equityUnavailable
Inventory$49.06M
Accounts receivable$34.01M
GoodwillUnavailable
Long-term debt$0
Accounts payableUnavailable

Cash flow

Axogen, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Operating cash flow$28.36M
Capital expenditures$6.32M
Investing cash flow-$22.36M
Financing cash flow$296.98M
Net change in cash$302.99M
Stock-based compensation$41.01M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$6.42M

Derived

Axogen, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Free cash flow$22.04M
Gross margin74.2%
Operating margin-5.2%
FCF margin8.3%
SBC / revenue15.4%
Current ratio12.02x
Revenue YoY growth24.3%
Net margin-12.0%
R&D / revenue14.0%
CapEx / revenue2.4%
Long-term debt / equity0.00x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AXGN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-28View SEC filing
10-Q · Filed 2026-07-29View SEC filing
10-Q · Filed 2026-04-28View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-08-05View SEC filing

Companies in the same industry

ADMT BLFS CBLL CNMD CV ECOR ELMD ESMC FOCL GTHP HCIL HYPR

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.